U.S. Consumer Durables Stock News

If you are wondering whether Copart's recent slide has turned it into a potential value opportunity, or if the market sees trouble ahead, this breakdown is for you. Copart is down about 0.1% over the last week, roughly 6.3% over the last month, and a steep 31.3% year to date, with the 1-year return sitting at around negative 36.8%. However, the 3- and 5-year returns are still positive at 28.1% and 26.4% respectively. These moves come as investors reassess the outlook for vehicle volumes,...

The Federal Reserve’s recent 25-basis-point interest rate cut, aimed at supporting economic growth through lower borrowing costs, has lifted sentiment toward consumer-facing companies like apparel and accessories maker VF Corp. This shift in monetary policy is especially relevant for VF Corp because easier credit conditions can encourage discretionary spending on branded clothing, footwear, and outdoor gear. Next, we’ll explore how the Fed’s signal of more supportive monetary policy could...

If you are wondering whether Semtech at around $72.89 is still worth a closer look, or if the big money has already been made, you are in the right place to work out what the current price really implies. The stock has pulled back about 8.4% over the last week, but it is still up 7.8% over 30 days and 17.4% year to date, with a 163.1% gain over 3 years that naturally raises questions about what comes next. Recent moves have been driven by growing investor attention on Semtech's role in...

In late September 2025, MoonLake Immunotherapeutics revealed that its only drug candidate, sonelokimab, delivered disappointing Phase 3 results, leading to multiple securities class action lawsuits alleging the company misled investors about the drug’s efficacy and Nanobody advantages. The litigation centers on claims that MoonLake overstated sonelokimab’s superiority versus an existing treatment while allegedly not fully disclosing their similar biological targets and unproven clinical...

The Brink's Company recently announced that its board approved a new share repurchase program authorizing up to US$750 million in buybacks, with the plan set to run through December 31, 2027. This authorization amounts to more than 15% of Brink's current market value, signaling management’s confidence in its cash generation and AMS/DRS-led growth strategy. Next, we’ll examine how Brink’s sizable new buyback authorization could reshape the existing investment narrative around capital...

In December 2025, Vestis Corporation reported fourth-quarter sales of US$712.01 million and a quarterly net loss of US$12.55 million, alongside a full-year net loss of US$40.22 million on sales of US$2,734.84 million, reversing the prior year’s profitability. Alongside these widened losses, Vestis guided for fiscal 2026 revenue to be flat to down 2% versus normalized 2025 levels, underscoring management’s cautious outlook on demand and execution. We’ll now examine how Vestis’s wider losses...

Wondering if Kroger at around $63 a share is still a smart buy or if the easy money has already been made? This breakdown is designed to give you a clear, valuation first answer. The stock is up 0.8% over the last week and 2.0% year to date, but that sits against a modest 3.9% gain over 1 year and much stronger returns of 52.4% over 3 years and 127.7% over 5 years, hinting at a long term uptrend that has cooled recently. Recent headlines have centered on Kroger's ongoing antitrust scrutiny...

RPC (RES) has been grinding through a mixed performance lately, with shares slipping over the past week but climbing about 27% in the past 3 months. This has left investors weighing value against cyclical risk. See our latest analysis for RPC. At around $5.68, RPC’s recent 90 day share price return of 27.07% contrasts with a weaker year to date performance. This suggests short term momentum is rebuilding even as longer term total shareholder returns remain uneven. If RPC’s rebound has you...

Wondering if JinkoSolar Holding at around $25.64 is a bargain or a value trap? You are not alone. This stock often flies under the radar despite big swings in sentiment. Over the last week the share price is up 5.9%, but that bounce comes after a choppy stretch, with the stock down 6.1% over 30 days and still negative over 1 year and even more over 3 and 5 years. Recently, JinkoSolar has stayed in the spotlight with ongoing headlines about global clean energy policy shifts and intensifying...

If you are wondering whether Monolithic Power Systems is still worth buying after its massive run, or if the best days are already priced in, you are not alone. The stock is trading around $946.51, down a modest 1.7% over the last week and 1.2% over the last month, but still up an impressive 59.3% year to date and 56.9% over the past year, with multi year gains above 160%. Recent enthusiasm has been driven by Monolithic Power Systems' expanding role in power management solutions for data...

Q3 2025 Snapshot and Recent Trends Evommune (EVMN) just posted Q3 2025 results with revenue of about $10 million and a basic EPS loss of roughly $8.07, while trailing twelve month figures show total revenue of about $13 million and basic EPS of around minus $40.87. Over recent periods the company has seen revenue move from roughly $5 million on a trailing basis in Q4 2023 to about $7 million in Q4 2024, then to around $13 million by Q3 2025, even as quarterly basic EPS remained negative...

Colgate-Palmolive (CL) is back on traders radar after RBC Capital bumped the stock to an outperform rating, arguing that consistent organic growth and solid execution could support a gradual sentiment reset. See our latest analysis for Colgate-Palmolive. That upgrade comes after a tough stretch, with the year to date share price return sitting around negative 13 percent and the 1 year total shareholder return near negative 14 percent. However, a positive 3 year total shareholder return just...

If you have ever wondered whether CoreCivic is quietly trading below what it is really worth, you are not alone and this article is going to walk through that question step by step. Despite being down 13.0% year to date and 13.6% over the last year, the stock has climbed 10.7% in the last month and 155.4% over five years, which reflects how quickly the market can move when expectations change. Recently, investors have been focused on CoreCivic's position in the U.S. corrections and detention...

Arcus Biosciences and partner Gilead Sciences have discontinued the Phase 3 STAR-221 trial after an interim analysis showed domvanalimab plus zimberelimab and chemotherapy did not improve overall survival versus nivolumab plus chemotherapy in first-line advanced gastric and esophageal cancers, though safety remained comparable. This setback is prompting Arcus to redirect development resources toward its HIF-2α inhibitor casdatifan and emerging small-molecule immunology and inflammation...

Wondering if Coeur Mining is still a bargain after its big run, or if you are late to the party? This breakdown will help you decide whether the current share price makes sense or is getting ahead of itself. The stock has rocketed, with shares up 8.8% over the last week, 10.4% over the past month, and 178.2% year to date, on top of a 163.0% gain over the last year and a 427.5% rise over three years. Recent moves have been closely tied to shifting sentiment around precious metals, as...

Wondering if Mondelez International is quietly turning into a value opportunity while the market looks elsewhere? You are not alone. The stock is down around 1.6% over the last week, 5.2% over the past month, and roughly 9.2% year to date. It is about 10.1% lower than a year ago despite being modestly positive, up 4.7%, over five years. Recently, investors have been digesting a mix of macro headlines around consumer spending, shifting brand loyalty in snacks and confectionery, and ongoing...

Universal Health Services (UHS) just delivered a standout third quarter, with revenue growth outpacing every major hospital peer and topping Wall Street forecasts, while full year EPS guidance also came in ahead of expectations. See our latest analysis for Universal Health Services. The strong quarter arrives after a solid run in the stock, with the share price at about $222.60 and a 90 day share price return of 16.11% pointing to building momentum. The 3 year total shareholder return of...

Labcorp Holdings (LH) just beat earnings expectations, but the stock is reacting more to management’s cautious tone after cutting revenue growth targets for its contract research unit and trimming its full year outlook. See our latest analysis for Labcorp Holdings. At around $264.18 per share, Labcorp’s recent weakness, reflected in a roughly 5 percent 3 month share price return, contrasts with a solid 5 year total shareholder return of about 57 percent. This suggests momentum has cooled as...

Wondering if AutoZone is still a smart buy after such a long run up, or if the easy money has already been made, you are not alone. The stock is up an impressive 191.5% over 5 years and 44.8% over 3 years, but more recently it has slipped 9.9% over the last week and 9.1% over the past month, leaving year to date gains at 6.0% and 1 year returns at 2.2%. Recent attention has focused on AutoZone's ability to keep winning in the do it yourself and commercial repair markets, as investors weigh...

Kolon Industries has announced in the past that it will invest in a new Vietnam plant to produce airbag materials for Autoliv, creating a fully integrated airbag manufacturing base in Ho Chi Minh City expected to be operational by 2028 under a long-term supply arrangement. This expansion deepens Autoliv’s access to critical airbag components in a cost-competitive region, potentially reinforcing supply resilience and supporting its global leadership in passive vehicle safety. We’ll now...

Wondering if Hormel Foods at around $24 a share is a bargain or a value trap? You are not alone, and this breakdown is designed to give you a clear, no-jargon view. The stock has bounced about 8.0% over the last month after a long slide, with the price still down roughly 23.9% over the past year and more than 40% over five years, which signals a big gap between past expectations and today’s sentiment. That recent rebound has come as investors refocus on Hormel’s portfolio reshaping and cost...

If you are wondering whether ON Semiconductor is quietly turning into a value opportunity, or if the market still sees too much risk in the story, you are not alone. The stock has inched up about 0.4% over the last week and 11.5% over the past month, but it is still down 10.9% year to date and 16.7% over the last year, a reminder that past enthusiasm has cooled even though the 5 year return sits at 74.3%. Recently, investors have been weighing ON Semiconductor's positioning in electric...

GigaCloud Technology stock moves GigaCloud Technology (GCT) has quietly turned into a strong momentum story, with the stock up about 26% over the past month and roughly 35% in the past 3 months. See our latest analysis for GigaCloud Technology. The latest jump takes GigaCloud Technology’s share price to $40.37, with a powerful year to date share price return of around 112 percent and a three year total shareholder return above 600 percent, suggesting momentum is still building as investors...

The Lovesac Company recently reported third-quarter fiscal 2026 results showing largely flat net sales at US$150.17 million alongside a wider net loss of US$10.55 million and higher loss per share than a year earlier. Despite weak profitability and below-consensus guidance for the key holiday quarter and full fiscal 2026, management is still investing in product innovation, domestic manufacturing, and marketing to expand its household reach over the long term. We’ll now examine how Lovesac’s...